chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I have been experiencing pins and needles in both arms and hands, and also, to a lesser extent, in my legs.; I am also having some achy pangs in associated areas.; I am also feeling fatigue and headaches.; I am also feeling fatigue and headaches.; This is a spontaneous report from a contactable consumer, the patient. A non-pregnant female patient of unknown age received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 17Apr2021 at 12:30 (age at vaccination unknown) as a single dose for COVID-19 immunisation. Medical history included scoliosis and back surgery (reported as scoliosis(spinal surgery)), asthma and allergic to tree nuts, peanuts and pollen. Concomitant medication received within two weeks of vaccination included multi-vitamin taken from unknown date for unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. From 17Apr2021 at 12:30, the patient has been experiencing pins and needles in both arms and hands, and also, to a lesser extent, in her legs. The patient was also having some achy pangs in associated areas. She was also feeling fatigue and headaches. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events has been experiencing pins and needles in both arms and hands, and also, to a lesser extent, in her legs; was also having some achy pangs in associated areas; was also feeling fatigue and headaches was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Pt found to be COVID positive after being transferred from ED due to right hip dislocation and NSTEMI. Pt had no symptoms at that time, but did develop hypoxia a day later.
215PM recvd vax; 3PM teary, red eyes; sneezing; resp congestion; 315PM return to clinic-runny nose, resp congest; pt went to MD given DPH;
Child was playing this am and child stated "I can't see".  Eyes appeared dialated, face pale, and lips were white.  S/S lasted aproximately 10-15 minutes.  Child also broke out into a "cold sweat".  8/17/06 PC to mother - had reported this event to child's neurologist and PCP.
localized swelling; hurts when she presses on it; her arm feels heavy and can't lift it that much; Injection site was red; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE ERYTHEMA (Injection site was red), INJECTION SITE SWELLING (localized swelling), INJECTION SITE PAIN (hurts when she presses on it) and INJECTED LIMB MOBILITY DECREASED (her arm feels heavy and can't lift it that much) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Jan-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INJECTION SITE ERYTHEMA (Injection site was red). On an unknown date, the patient experienced INJECTION SITE SWELLING (localized swelling), INJECTION SITE PAIN (hurts when she presses on it) and INJECTED LIMB MOBILITY DECREASED (her arm feels heavy and can't lift it that much). At the time of the report, INJECTION SITE ERYTHEMA (Injection site was red), INJECTION SITE SWELLING (localized swelling), INJECTION SITE PAIN (hurts when she presses on it) and INJECTED LIMB MOBILITY DECREASED (her arm feels heavy and can't lift it that much) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided.  No concomitant medication was provided.
Redness of site of Injection, still spreading after 5 days even after use of an ice pack. Recommended to go to ER.
Covid vaccine on the late afternoon of 7-5-21. At 11pm, general body aches turned into horrific pain all over her body. Described as stabbing pain and electric shocks.   Headache, stomachache and crying.  At 10am on 7-6-21, she had chest pains and a heart rate of 170.  We drove to the ER.  By the time she was checked into ER, heart rate was 150 and she had a fever of 101.9 Tachycardia treated with large dose of Versed given in IV?did not work.  Toroidal given for pain to reduce fever. That worked.  Heart rate staying at 130 and she is in horrible pain.  X-rays, lab work. Atavan given at 3:40pm which helped calm her.  But heart rate stayed at 130.  Inflammatory blood work was elevated. D-Dimer test was elevated. CT scan normal.  At 2:30am on 7-7-21, Pt finally fell asleep.  She woke up with a normal heart rate in the 80s by 7am. Critical care doctors consulted with cardiology and examined her. Pain was gone, fever gone, and heart rate was normal. They think the Covid vaccine caused her tachycardia and caused a fibromyalgia flare up with her extreme pain.     Extreme pain all over body ?electric pain.  Headache Stomachache  Chest pains
injection site - Redness, hot to touch,  swelling, soreness, prolonged.
Office would draw up all COVID booster vaccines at the beginning of the day and discard vial. They kept a sticky note with bivalent, lot and expiration date and used that data to enter into the EMR. At some point the realized that on some days they had pulled and administered monovalent instead of the bivalent booster as intended. Office is unable to say with certainty who received monovalent or bivalent.
Pulmonary fibrosis rapidly progressed & flare up after moderna covid 19; This spontaneous case was reported by a health care professional and describes the occurrence of IDIOPATHIC PULMONARY FIBROSIS (Pulmonary fibrosis rapidly progressed & flare up after moderna covid 19) in a 73-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for an unknown indication.     Concurrent medical conditions included Idiopathic pulmonary fibrosis. Concomitant products included PIRFENIDONE (ESBRIET) for an unknown indication.    On 04-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced IDIOPATHIC PULMONARY FIBROSIS (Pulmonary fibrosis rapidly progressed & flare up after moderna covid 19) (seriousness criteria hospitalization and medically significant). At the time of the report, IDIOPATHIC PULMONARY FIBROSIS (Pulmonary fibrosis rapidly progressed & flare up after moderna covid 19) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment details were not provided. Patient was stabilized since first encounter on 7-Mar-2018.  Company comment: This is a spontaneous case concerning a 73-year-old male patient with concurrent condition of idiopathic pulmonary fibrosis treated with Esbriet, and no other medical history reported, who experienced the serious, unexpected, according CCDS, event of idiopathic pulmonary fibrosis. The event occurred on an unknown date after the second dose of mRNA-1273 vaccine. The medical history of atrial fibrillation remains a confounder for atrial fibrillation. The concurrent condition of idiopathic pulmonary fibrosis remains a confounder. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a 73-year-old male patient with concurrent condition of idiopathic pulmonary fibrosis treated with Esbriet, and no other medical history reported, who experienced the serious, unexpected, according CCDS, event of idiopathic pulmonary fibrosis. The event occurred on an unknown date after the second dose of mRNA-1273 vaccine. The medical history of atrial fibrillation remains a confounder for atrial fibrillation. The concurrent condition of idiopathic pulmonary fibrosis remains a confounder. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.
I received the Moderna vaccine at 3:50pm on 01/25/2021. Around 3:30am on 01/26/2021 I awoke feeling feverish and nauseous, and my arm at the site of injection was extremely painful. For the next 4 hours, I drifted in and out of sleep as I experienced violent body shakes from chills. Around 7:00am I woke up feeling more nauseous, and my temperature read 99.7 F. I vomited once, just containing stomach acid. After vomiting the nausea subsided but I had a pounding headache with sensitivity to light, joint and muscle aches, and continued pain at the site of the injection, although no redness or swelling was noticeable. The headache and injection site pain improved a little bit with Tylenol. At 11:20am 01/26/2021, I am now experiencing a mild headache and body aches, and my temperature reads 99.1 F.
Every joint in my body lit up with severe pain, including my spine. I was fine the day of the vaccination, but the following day in art class, I was sitting down and turned back to get a pencil to start drawing, and my entire spinal cord lit up in terrible pain, to the point that I screamed a little bit in shock and in pain. The entire day I was so fatigued in my shoulders, arms, hands and legs. It hurt to move to the point that I wanted to lay down, but I hung in there, not realizing or remembering that I had the Shingrix vaccine the day before. I went to drive home from my art college, but turning my head side to side was so painful. I had to manually move my head with my hand, and I drove very carefully home. I ran to the store on my way home to buy Tylenol XS, and I took 2 pills as I was standing in line at checkout. It was very painful, and I finally arrived home to hobble to my bed to rest. I fell asleep for 3 solid hours, I was in so much pain and my joints ached like something I never experienced in my life. I had to write to report this adverse reaction - I will NEVER consent to the second dosage of the Shingrix vaccination. The side effects were too harsh, too severe, too long - lasting. I had to deal with this arthritic type of pain for 2 full weeks before it calmed itself down. It felt like all of my joints were a rusted door on a boat. It was terrible.
Pt had a seizure: eyes closed, frothing at the mouth, pt collapsed, arms extended & pronated with fists clenched.  Seizure occurred within 2 mins after vaccinated.  Seizure lasted 10-15 secs; pt recovered completely.
the site is still hot and swollen; the site is still hot; This case was reported by a consumer via (Shingrix GSK and described the occurrence of injection site swelling in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On 22nd April 2021, the patient received Shingrix. In April 2021, less than a week after receiving Shingrix, the patient experienced injection site swelling and injection site warmth. On an unknown date, the outcome of the injection site swelling and injection site warmth were not recovered/not resolved.   It was unknown if the reporter considered the injection site swelling and injection site warmth to be related to Shingrix.  Additional details were reported as follows: This case was reported by patient himself/herself. The age group was not reported but was selected as an adult as per vaccine indication. The age at vaccination was not reported. The patient received Shingrix and the site was still hot and swollen. The patient inquired was this normal. The follow-up would not possible as no contact details were available.
Next day after of tired, fatigue, muscle ache, chills, arm ache, shortness of break  and took a tylenol.  01/13/2021 walk -in clinic and  high heart rate and shortness of breath and fatigue.  Covid -19  positive  12/04/2020
It made my improving parosmia and dysgeusia worse; It made my improving parosmia and dysgeusia worse; Condition aggravated; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FE3590) via an unspecified route of administration in the left arm on 13Oct2021 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. The patient had known unspecified allergies. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. On 18Oct2021, it was reported that the vaccination made his improving parosmia and dysgeusia worse. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events it made his improving parosmia and dysgeusia worse was not resolved at the time of this report. The patient also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 32030BD) via an unspecified route of administration in the left arm on 03Nov2021 (at the age of 32-years-old) as a single dose for COVID-19 immunisation.
On 11/3, recieved influenza vaccine.On approx 11/21, presented with signs of an upper respiratory tract infection with cough,mucus, and sore throat.  He was started on amoxicillin.On 11/28, pt became weak in the legs and had trouble walking.  On 11/29, he was crawling around the house as he could not walk due to weakness.  He was admitted to the hospital on 11/30 with dx Guillian-Barre. He is presently in Intensive Care receiving IVIG 1/22/09-records received for DOS 11/30-12/26/08. DC DX:Guillain Barre Syndrome. Pulmonary embolus. Transaminitis. Hypertension. Presented with developing progressive parapersis and weakness of upper and lower extremities to point unable to walk around and began crawling. Treated with IV gamma globulins. Developed acute pulmonary embolus.
Resident had shortness of breath and low O2 sat (55%). He was taken by his daughter to the Medical Center. He was admitted into the ICU due to COVID vaccine side effects.
This spontaneous report as received from a pharmacist refers to a patient of unknown age and gender. On 23-MAY-2014 the patient was vaccinated with PNEUMOVAX23, 0.5 ml, intramuscular, lot # h018944, expiration date 01-MAR-2014; location of administration was not reported. The patient received expired dose of PNEUMOVAX23 on 23-MAY-2014. No adverse effect reported. Additional information has been requested.
Patient began feeling very dizzy and nauseous, then when she sat up after resting for 20 mins felt a sudden onset of chest pain. EKG and vitals looked normal. EMS was called and patient was transferred to hospital.
Pfizer COVID Vaccine EUA: COVID-19 case resulting in Hospitalization / Death. Patient received Pfizer Vaccine on 3/05/2021 and 3/26/2021. Presented to ED 2/7/22 with SOB. Admitted for acute hypoxemic respiratory failure 2/2 Covid-19 PNA c/b severe COPD, AFib with RVR. Placed on HFNC O2 and given IV metoprolol. She was on hospice at home and her prognosis was poor. Patient was transitioned to comfort care. Treated with solumedrol and ceftriaxone. Patient expired 02/12/22.
This spontaneous report as received from a Licensed Practical Nurse refers to an unspecified amount of patients of unknown age and gender. On an unknown dates the patients were vaccinated with doses of Oral, ROTATEQ that underwent temperature excursions. No adverse effect reported. This is one of several reports from the same source. Additional information has been requested.
12-13 Petechiae on left forearm onset 12 days after second Moderna dose. 1 on right eyelid onset day 13. Blood work showed normal platelets. No other symptoms. Petechiae began fading 1 day after onset. Eyelid petechiae still present.
Severe pain with itching hives, that started ion back and spread  with nausea.
She is asking if it's okay to take it further than her scheduled 2nd dose; she has lymphadenopathy; This is a spontaneous report from a non-contactable consumer (patient) via a Pfizer sponsored program. A 73-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, batch/lot number and expiration date: not reported), via an unspecified route of administration on 09Jun2021 as dose 1, single for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. On an unknown date in Jun2021, the patient experienced lymphadenopathy. The clinical course of the events was reported as she received the 1st dose of our COVID-19 vaccine last 09Jun2021 and scheduled for the 2nd dose on 08Jul2021 (29 days apart). She claimed that her daughter just read about the new update that it was okay to take the 2nd dose within a maximum of 42 days. If this was so, she was asking if it was okay to take it further than her scheduled 2nd dose because she had lymphadenopathy (as long as it would not exceed 42 days). She was also asking if there would be side effects when she did take the 1st dose and not knowing that it might affect people with swelling of the lymph nodes. The outcome of the events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
There wasn't an adverse reaction to the vaccination, the vaccine was administered outside of the ACIP guideline recommended age range, the patient is only 46 years old.
Lesioins on face, trunk and extremities x 4 days.  Afebrile.  Prescribed: Atarax.
Pt experienced excessive abdominal pain/ discomfort after several days of receiving the first dose of SHINGRIX.
Pt complained of full body itching . Denied difficulty breathing or any other complaints. She agreed to Benadryl 25 mg IM to resolve symptoms.  Itching began to resolve immediately. 30 minutes later itching was almost fully resolved and pt had no other signs/ symptoms. She left ambulatory planning to go directly home.
vaccine exposure during pregnancy; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (vaccine exposure during pregnancy) in a 35-year-old female patient (gravida 3, para 1) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011J20A) for COVID-19 vaccination.     The patient's past medical history included Miscarriage (In NOV-2019, at 8 or 9 weeks), Alcohol use (1-2 glasses of wine a week.) and Delivery (Pregnancy outcome: Live, full-term birth) on 21-Nov-2017. Concurrent medical conditions included Hypothyroidism since 2017. Concomitant products included MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]) and LEVOTHYROXINE for an unknown indication.    On 07-Jan-2021 at 9:00 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on an unknown date and the estimated date of delivery was 02-Feb-2021. On 07-Jan-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (vaccine exposure during pregnancy). The delivery occurred on an unknown date, which was reported as Unknown. For neonate 1, The outcome was reported as Unknown. On 07-Jan-2021, MATERNAL EXPOSURE DURING PREGNANCY (vaccine exposure during pregnancy) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Glucose tolerance test: normal (normal) normal. On an unknown date, Prenatal screening test: normal (normal) Normal. On an unknown date, Scan: normal (normal) normal.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment information was provided by the reporter.; Sender's Comments: This is a case of product exposure during pregnancy with no associated AEs for this 35-year-old female. Patient will continue to be contacted for further monitoring of AEs during the pregnancy
SM had large local reaction with his 3rd and 4th anthrax shots.  Symptom: Edema @ injection site 50-120mm Start: 06/2003; Edema @ injection site 50-120mm Start: 09/2004; Pain Start: 06/2003; Erythema Start: 09/2004; Pain Start: 09/2004
I developed an ovarian cyst in my right ovary. It is currently being monitored. A surgery may be needed to resolve at a later date.
Patient came in for 2nd dose of Pfizer vaccine series. The 2nd dose administering clinician noticed the patient's previous vaccination record in the EHR reflected a pediatric dose amount (0.2mL) and lot number associated with pediatric Pfizer (FK5127). Patient's age at both 1st and 2nd dose was 13 years. Clinician proceeded to administer the correct and appropriate Pfizer dose for 12+ (0.3mL, lot # FE3590) for the patient's 2nd dose.
First day I had hives and start taking Benadryl. Next day I had swollen in arm. I was hurting everywhere. I had trouble hearing and could not walk. It felt as if I was stab in my ear. The pain in my ear I was not able to sleep. That following Saturday I visit urgent care. I was dizzy, coughing, and sneezing. Doctor stated I had upper respiratory infection. Sunday I had diarrhea. Also I was told I had fluid behind the ears.
This spontaneous report as received from a registered nurse refers to a male patient of unknown age. Patient's pertinent medical history, concurrent condition and concomitant medication were not reported. No previous drug reactions/ allergies were reported. On an unknown date the patient was vaccinated with M-M-R II (strength, dosing details, anatomical location, lot# and expiration date were unknown). On an unknown date, following the vaccination, an unknown type of serologic testing was performed to assess the patient's immunity. The test results showed that the patient has low immunity to an unknown component of the vaccine. No adverse effects were reported. The outcome of decreased immune responsiveness was unknown. Causality assessment was not provided. No product quality complaint was filed. Additional information has been requested.
Given after FDA emergency use authorization was removed for boosters. Submitting as recommended from CDC meeting, 9/1/22
Patient experienced perioral tingling and swelling after dose #1. Experiencing tingling few minutes  After administration of dose # 2 today. Benadryl 25mg PO administered. Monitored for 15 minutes. Denies any trouble swallowing, SOB, or swelling. Patient was discharged home
Pt recvd Engerix-B vax & 12MAR92 exp hives on chest, some on face & knees; swollen lips; high BP 186/126 & SOB; doses 2 & 3 have not been given; poss allergic response;
pt recvd vax &  devel t 104; sz like activity; shaking, rolling eyes; brief sz on 24sep94; ran fever; pt vomitted x 4 days;
I had tachycardia 6 hours after receiving my vaccination.  During the night I was unable to sleep due to chills and fever. The next day I had body aches, fatigue, vomiting, lightheadedness. I slept for several hours the day after. Arm was also sore and difficult to move.
Tender/ hard to touch at injection site Advised to use Motrin, Benadryl & ice as needed F/u if symptoms persist or worsen
Patient was inconsolable and irritable and had a fever up to 103 degrees.  Started at 3:30 PM 6/23/10 and was back to normal by next AM.
Arm was very painful, woke up to neck sore on left side where shot given, later felt prickly sensation & rash started to appear near where shot was given. Continued to get worse went back to doctor 3/2/12 said was strange reaction. Continued to get worse. 3/4/12 went to Urgent Care & they said it was shingles. That night felt like I was on fire at the sight. 3 weeks later still recovering from rash. I do believe this was triggered by the vaccine. I had no precursor symptoms, came on suddenly. Also I didn't have chicken pox as a kid, so was vaccinated 6 yrs ago.